Alan Fuhrman

Alan Fuhrman

Director of Finance/CFO at TYRA BIOSCIENCES, INC.

Net worth: 540 039 $ as of 31/05/2026

69 year
Health Technology
Electronic Technology
Commercial Services

Profile

Alan Fuhrman is currently Director at Life Science Washington, Director at SpringWorks Therapeutics LLC since 2019, and Chief Financial Officer at Tyra Biosciences, Inc. starting in 2026.
Former roles include Independent Director at Springworks Therapeutics, Inc. from 2019 to 2025, Independent Director at Loxo Oncology, Inc. from 2015 to 2019, Independent Director at Checkmate Pharmaceuticals, Inc. in 2022, Independent Director at Esperion Therapeutics, Inc., Chief Financial Officer & Senior Vice President at Sonus Pharmaceuticals, Inc. from 2004 to 2008, Chief Financial Officer at NeoPath, Inc., Chief Financial Officer & Vice President at Naviscan, Inc. from 2008 to 2010, Chief Financial Officer at Capital Stream, Inc. in 2002, President & Chief Operating Officer at Integrex, Inc. in 2004, Chief Financial Officer at Medisystems Corp., CFO & Principal Accounting Officer at Mirna Therapeutics, Inc. from 2015 to 2017, Chief Financial Officer at Amplyx Pharmaceuticals, Inc. from 2017 to 2020, and Chief Financial Officer at Ambit Biosciences Corp.
from 2010 to 2014.
Education includes undergraduate studies at Montana State University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
05/05/2026 16,164 ( 0.03% ) 540 039 $ 31/05/2026

Alan Fuhrman active positions

CompaniesPositionStart
TYRA BIOSCIENCES, INC. Director of Finance/CFO 01/01/2023
Director/Board Member 30/08/2019
Director/Board Member -

Former positions of Alan Fuhrman

CompaniesPositionEnd
SPRINGWORKS THERAPEUTICS, INC. Director/Board Member 01/07/2025
CHECKMATE PHARMACEUTICALS, INC. Chief Executive Officer 01/03/2022
Director of Finance/CFO 01/06/2020
LOXO ONCOLOGY INC Director/Board Member 15/02/2019
Director of Finance/CFO 01/08/2017
See the detail of Alan Fuhrman's experience

Training of Alan Fuhrman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

59

1st degree connections

17

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies17

Health Technology

Health Technology

Health Technology

Electronic Technology

Health Technology

Technology Services

Electronic Technology

Consumer Services

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology